CYTOSORBENTS CORP (CTSO)
US23283X2062 - Common Stock
Taking everything into account, CTSO scores 2 out of 10 in our fundamental rating. CTSO was compared to 187 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of CTSO have multiple concerns. While showing a medium growth rate, CTSO is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year CTSO has reported negative net income.
In the past year CTSO has reported a negative cash flow from operations.
In the past 5 years CTSO always reported negative net income.
CTSO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -39.06%, CTSO is not doing good in the industry: 60.75% of the companies in the same industry are doing better.
Looking at the Return On Equity, with a value of -143.63%, CTSO is doing worse than 72.58% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -39.06% | ||
| ROE | -143.63% | ||
| ROIC | N/A |
ROA(3y)-44.28%
ROA(5y)-42.39%
ROE(3y)-84.83%
ROE(5y)-165.57%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 62.71%, CTSO is in the better half of the industry, outperforming 63.98% of the companies in the same industry.
In the last couple of years the Gross Margin of CTSO has declined.
The Profit Margin and Operating Margin are not available for CTSO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 62.71% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.52%
GM growth 5Y-1.58%
2. Health
2.1 Basic Checks
CTSO does not have a ROIC to compare to the WACC, probably because it is not profitable.
CTSO has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CTSO has more shares outstanding
Compared to 1 year ago, CTSO has a worse debt to assets ratio.
2.2 Solvency
CTSO has an Altman-Z score of -8.26. This is a bad value and indicates that CTSO is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of CTSO (-8.26) is worse than 76.88% of its industry peers.
A Debt/Equity ratio of 1.06 is on the high side and indicates that CTSO has dependencies on debt financing.
With a Debt to Equity ratio value of 1.06, CTSO is not doing good in the industry: 76.88% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.06 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -8.26 |
ROIC/WACCN/A
WACC9.09%
2.3 Liquidity
CTSO has a Current Ratio of 1.97. This is a normal value and indicates that CTSO is financially healthy and should not expect problems in meeting its short term obligations.
CTSO has a Current ratio of 1.97. This is in the lower half of the industry: CTSO underperforms 67.20% of its industry peers.
A Quick Ratio of 1.58 indicates that CTSO should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.58, CTSO perfoms like the industry average, outperforming 41.40% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.97 | ||
| Quick Ratio | 1.58 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 31.48% over the past year.
Looking at the last year, CTSO shows a small growth in Revenue. The Revenue has grown by 1.81% in the last year.
CTSO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.07% yearly.
EPS 1Y (TTM)31.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80.95%
Revenue 1Y (TTM)1.81%
Revenue growth 3Y-3.93%
Revenue growth 5Y10.07%
Sales Q2Q%6.58%
3.2 Future
CTSO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.26% yearly.
The Revenue is expected to grow by 27.17% on average over the next years. This is a very strong growth
EPS Next Y52.92%
EPS Next 2Y29.65%
EPS Next 3Y23.07%
EPS Next 5Y15.26%
Revenue Next Year4.27%
Revenue Next 2Y8.45%
Revenue Next 3Y12.72%
Revenue Next 5Y27.17%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
CTSO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CTSO. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
CTSO's earnings are expected to grow with 23.07% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.65%
EPS Next 3Y23.07%
5. Dividend
5.1 Amount
No dividends for CTSO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CYTOSORBENTS CORP
NASDAQ:CTSO (1/3/2025, 8:00:01 PM)
After market: 0.944 +0.01 (+0.79%)0.9366
+0.02 (+1.8%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners34.64%
Inst Owner Change-1.69%
Ins Owners3.29%
Ins Owner Change5.84%
Market Cap51.35M
Analysts80
Price Target5.1 (444.52%)
Short Float %2.65%
Short Ratio9.38
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)28.82%
Min EPS beat(2)19.56%
Max EPS beat(2)38.08%
EPS beat(4)4
Avg EPS beat(4)16.73%
Min EPS beat(4)1.96%
Max EPS beat(4)38.08%
EPS beat(8)5
Avg EPS beat(8)6.56%
EPS beat(12)5
Avg EPS beat(12)-18.48%
EPS beat(16)6
Avg EPS beat(16)-32.02%
Revenue beat(2)1
Avg Revenue beat(2)-4.67%
Min Revenue beat(2)-9.58%
Max Revenue beat(2)0.24%
Revenue beat(4)1
Avg Revenue beat(4)-4.94%
Min Revenue beat(4)-9.58%
Max Revenue beat(4)0.24%
Revenue beat(8)3
Avg Revenue beat(8)-3.91%
Revenue beat(12)4
Avg Revenue beat(12)-5.3%
Revenue beat(16)5
Avg Revenue beat(16)-5.2%
PT rev (1m)-9.09%
PT rev (3m)11.11%
EPS NQ rev (1m)0%
EPS NQ rev (3m)13.04%
EPS NY rev (1m)0%
EPS NY rev (3m)6.98%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.49%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.75%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.36 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.95 | ||
| P/tB | 3.95 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.37
EYN/A
EPS(NY)-0.21
Fwd EYN/A
FCF(TTM)-0.35
FCFYN/A
OCF(TTM)-0.34
OCFYN/A
SpS0.69
BVpS0.24
TBVpS0.24
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -39.06% | ||
| ROE | -143.63% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 62.71% | ||
| FCFM | N/A |
ROA(3y)-44.28%
ROA(5y)-42.39%
ROE(3y)-84.83%
ROE(5y)-165.57%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.52%
GM growth 5Y-1.58%
F-Score5
Asset Turnover0.79
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.06 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 39.83% | ||
| Cap/Sales | 1.81% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.97 | ||
| Quick Ratio | 1.58 | ||
| Altman-Z | -8.26 |
F-Score5
WACC9.09%
ROIC/WACCN/A
Cap/Depr(3y)461.47%
Cap/Depr(5y)380.21%
Cap/Sales(3y)10.37%
Cap/Sales(5y)8.26%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80.95%
EPS Next Y52.92%
EPS Next 2Y29.65%
EPS Next 3Y23.07%
EPS Next 5Y15.26%
Revenue 1Y (TTM)1.81%
Revenue growth 3Y-3.93%
Revenue growth 5Y10.07%
Sales Q2Q%6.58%
Revenue Next Year4.27%
Revenue Next 2Y8.45%
Revenue Next 3Y12.72%
Revenue Next 5Y27.17%
EBIT growth 1Y22.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year48.76%
EBIT Next 3Y28.62%
EBIT Next 5YN/A
FCF growth 1Y47.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.87%
OCF growth 3YN/A
OCF growth 5YN/A